ATOPIC DERMATITIS

This study tested a drug called tralokinumab for people with moderate-to-severe atopic hand eczema that hasn't improved with standard treatments. 235 adults received either the drug or a placebo every two weeks for 16 weeks, then everyone got the drug for another 16 weeks. The go…

This study tested an experimental drug called LNK01001 in 356 adults with moderate to severe atopic dermatitis (eczema) who had not responded well to standard creams or needed stronger treatment. Participants received either the drug or a placebo, and researchers measured improve…

This study tested a new medicine called UCB1381 in healthy people and those with moderate to severe eczema (atopic dermatitis). The main goals were to see if the drug is safe and to measure how well it clears skin rashes compared to a placebo. The trial involved 273 participants …

This study tested a drug called lebrikizumab in 86 adults and teenagers with moderate-to-severe eczema who had already tried dupilumab. The goal was to see if lebrikizumab could safely improve skin symptoms like redness, swelling, and itching. Participants received lebrikizumab a…

This study looked at whether adding Chinese herbal medicine to standard care can help people with moderate to severe eczema (atopic dermatitis). Nineteen people aged 6 to 30 took part. Researchers measured skin symptoms and quality of life before and after treatment. The goal was…

This study looked at the safety and effectiveness of upadacitinib, a drug already approved for eczema, in 167 teenagers aged 12 to 18 in Japan. Researchers tracked side effects and how well the drug worked over 2 years in everyday medical practice. The goal was to confirm the dru…

This study looked at how dupilumab affects the skin barrier in 44 Chinese patients with moderate to severe atopic dermatitis (eczema). Over 16 weeks, researchers measured water loss from the skin to see if the treatment helped strengthen the barrier. The goal was to understand ho…

This study tested a new medicine called rocatinlimab, given as an injection, along with standard topical creams, in 746 adults with moderate-to-severe eczema (atopic dermatitis). The goal was to see if the combination could clear the skin and reduce itching better than creams alo…

This study tested a new drug called AK120 in 450 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check for side effects and see how well the drug works. Researchers measured changes in eczema severity using standard skin scores.

This study tested a new medicine called UCB9741 in healthy volunteers and people with moderate-to-severe atopic dermatitis (eczema). The main goal was to check if the drug is safe and how the body processes it. Researchers also looked for early signs that the drug might improve e…

This study tested the long-term safety and effectiveness of lebrikizumab, an injectable drug, for adults with moderate-to-severe eczema (atopic dermatitis). Over 1,100 participants who had already been in earlier lebrikizumab studies were followed for up to 33 months. The main go…

This study tested whether teenagers and adults with moderate-to-severe eczema (atopic dermatitis) could successfully give themselves injections of the drug rocatinlimab at home using special devices. The main goal was to see how many full doses were self-administered correctly up…

This study tested a drug called dupilumab in Japanese children aged 6 months to 18 years with moderate-to-severe eczema that was not controlled by standard treatments. Participants received either dupilumab or a placebo, along with topical steroids, for 16 weeks. The goal was to …

This study tested a new medicine called rocatinlimab for adults with moderate-to-severe eczema (atopic dermatitis). 769 people took part. The goal was to see if the drug could clear the skin and reduce itching better than a placebo over 24 weeks. Results showed meaningful improve…

This study tested an oral medication called upadacitinib in 912 teenagers and adults with moderate to severe eczema (atopic dermatitis) that was not well controlled with creams. The goal was to see if the drug could significantly clear the skin rash and reduce itching compared to…

This study tested a drug called tralokinumab in 28 children aged 6 to 12 with moderate-to-severe eczema. The goal was to see how the drug moves through the body and if it is safe and effective. Children received injections over many weeks and used moisturizer daily. The drug aims…

This study tested a new medicine called BSI-045B in 22 adults with moderate to severe atopic dermatitis (eczema). Participants received injections weekly for 4 weeks, then every 2 weeks for 20 more weeks. The main goal was to see if the treatment could reduce eczema severity by a…

This study tested a drug called lebrikizumab in 90 adults and teens with moderate-to-severe eczema who have skin of color. The goal was to see if the drug safely improves eczema symptoms, like redness and itching, over 24 weeks. Participants received the drug and were checked for…

This study tested a new medicine called LEO 138559 (also known as Temtokibart) in 262 adults with moderate-to-severe eczema. Participants received one of four doses of the drug or a placebo as injections under the skin for 16 weeks. The goal was to see if the drug safely reduces …

This study tested whether a moisturizer containing postbiotics (helpful yeast and bacteria) can lower the chance of eczema returning in children aged 0-6 years whose eczema was in remission. 98 children took part, and researchers tracked how many had flare-ups compared to those u…

This study tested whether baricitinib (a newer pill) works better than azathioprine (an older pill) for adults with moderate-to-severe eczema. Both groups also used steroid creams. The trial involved 40 adults and measured skin improvement after 12 weeks. The goal is to find a mo…

This study tested a drug called rocatinlimab in 532 teenagers aged 12 to 17 with moderate-to-severe eczema that didn't get better with standard creams. The goal was to see if the drug could clear the skin and reduce itching. Participants received either the drug or a placebo for …

This study tested a new medicine called rocatinlimab in 187 teenagers aged 12 to 17 with moderate-to-severe eczema (atopic dermatitis). The main goal was to see if the drug is safe and tolerable over 52 weeks. Participants had not responded well to standard creams or ointments. T…

This study tested whether a team-based online care model works as well as traditional in-person visits for managing atopic dermatitis (eczema). 300 patients were randomly assigned to either online or in-person care for 12 months. The main goal was to see if eczema severity improv…

This study tested a new medication called SIM0718 in 259 adults and teenagers (ages 12-75) with moderate to severe atopic dermatitis (eczema). The goal was to see if it improves skin symptoms like redness and itching compared to a placebo. Participants received either the drug or…

This study tested a new medicine called camoteskimab in 62 adults with moderate to severe eczema (atopic dermatitis). The goal was to see if it could reduce skin redness, itching, and rash better than a placebo over 12 weeks. Participants received either the drug or a placebo, an…

This study tested whether methotrexate works as well as cyclosporine for adults with moderate to severe eczema. About 100 participants received one of the two drugs for 24 weeks. The goal was to see how many people had a 50% improvement in their eczema symptoms after 8 weeks.

This study looked at how dupilumab, a medication for moderate to severe eczema, improves the skin's barrier function. Researchers measured water loss from the skin in 52 participants before and after treatment. The goal was to understand how well the drug helps restore the skin's…

This study looked at the long-term safety and effectiveness of lebrikizumab for adults and teens with moderate-to-severe atopic dermatitis (eczema). Participants who had already completed a previous study were given lebrikizumab for up to 2 more years. The goal was to see how man…

This study tested a daily pill called upadacitinib in over 900 teens and adults with moderate to severe eczema (atopic dermatitis) who needed stronger treatment. The goal was to see if the drug could clear skin and reduce itching better than a placebo. Results showed significant …

This study tested a new medicine called CM310 in 180 teenagers with moderate-to-severe eczema (atopic dermatitis). The goal was to see if it could clear skin and reduce itching better than a placebo. Results showed that more teens using CM310 had significant skin improvement by w…

This study tested a new treatment called STMC-103H in babies and young children who are at risk for developing allergies because of their family history. The goal was to see if it is safe and can prevent or delay the onset of allergic conditions like eczema and food allergies. Pa…

This study looked at whether adding group psychotherapy to standard eczema care can improve symptoms in adults with moderate-to-severe atopic dermatitis (eczema). Thirty-two participants were split into three groups: standard care alone, standard care plus cognitive behavioral th…

This study looked at whether a moisturizing cream (RV4427C WM0071) helps people with moderate to severe atopic dermatitis (eczema) who are already on systemic treatments. About 80 adults used the cream and answered questionnaires about their skin, satisfaction, and habits. The go…

This study tested whether adding vitamin K2 (45 mg daily for 12 weeks) to standard treatment can reduce eczema severity in 100 children aged 6-12 with moderate to severe atopic dermatitis. Researchers measured changes using the SCORAD score and looked at immune markers and choles…

This study tested whether dupilumab, an injectable drug, improves sleep in 188 adults with moderate to severe eczema who also had trouble sleeping. Participants received either dupilumab or a placebo for 12 weeks. The main goal was to see if sleep quality ratings improved, with s…

This study tested whether taking a daily probiotic called Bifidobacterium longum CCFM1029 could help ease eczema in infants aged 3 months to 3 years. 100 children were split into two groups: one received the probiotic and the other a placebo for 3 months. Researchers tracked chan…

This study tested a behavioral therapy called EMD-U for people with atopic dermatitis (eczema) or prurigo nodularis who scratch severely. 96 adults were randomly assigned to receive either EMD-U plus usual care or usual care alone. The goal was to see if EMD-U improved skin-relat…

This study tested two creams—crisaborole and fluticasone—on 40 children aged 1 to 12 with mild to moderate eczema. Both creams were applied twice daily for 6 weeks, then twice weekly for 12 weeks if the skin improved a lot. Both treatments helped reduce itching and skin redness, …

This study tested a new ointment called YR001 in 35 adults with mild to moderate atopic dermatitis (eczema). The main goal was to check if the ointment is safe and how the body processes it. Researchers also looked at whether it improves skin symptoms like redness and itching.

This study tested a cream called tapinarof for people aged 2 and older with moderate to severe eczema (atopic dermatitis). Over 400 participants used either the study cream or a placebo cream for 8 weeks. The goal was to see if the cream could clear or nearly clear the skin rash.…

This study tested a cream called tapinarof in 407 people aged 2 and older with moderate to severe atopic dermatitis (eczema). The goal was to see if the cream could clear or nearly clear the skin rash and reduce itching after 8 weeks of daily use. Participants were randomly assig…

This study tested an experimental ointment called LNK01004 in 75 adults with moderate to severe atopic dermatitis (eczema). Participants applied the ointment twice daily for 8 weeks. The goal was to see if it safely reduces eczema severity and improves skin symptoms compared to a…

This study tested a new cream called VC005 on 118 adults with mild to moderate atopic dermatitis (eczema). The goal was to see if it safely reduces eczema symptoms like redness and itching. Participants used the cream or a placebo for a period, and doctors measured changes in the…

This study looked at how well the drug upadacitinib works for people with moderate to severe eczema who also have hard, itchy bumps called prurigo nodularis. About 200 adults and teens in Japan took a daily pill for 48 weeks. The main goal was to see if their worst itch got much …

This study tested a special moisturizer containing a friendly bacteria (Lactobacillus reuteri) to see if it could improve eczema symptoms in children. Forty kids aged 6 months to 12 years with mild-to-moderate eczema used the cream for 8 weeks. Researchers measured changes in the…

This study tested whether a measles vaccine could improve symptoms of atopic dermatitis (eczema) in adults. Twenty adults with moderate to severe eczema received either the vaccine or a placebo and were followed for 45 days. The goal was to see if the vaccine could calm the immun…

This study tested a cream called tapinarof in 36 children aged 2 to 17 with moderate-to-severe eczema covering large body areas. The goal was to see how much of the drug enters the body and if it causes side effects. Researchers monitored safety through blood tests, vital signs, …

This early-stage study tested a new medicine called BSI-045B in 54 healthy volunteers and people with eczema (atopic dermatitis). The main goal was to check if the drug is safe and tolerable. Researchers gave different doses as injections under the skin and monitored side effects…

This study tested a new cream called PRN473 on 39 adults with mild to moderate eczema. Each person had two patches of eczema treated: one with the study cream and one with a placebo cream. The goal was to see if the cream is safe and helps reduce skin symptoms. The study lasted a…

This early-stage study tested a new medicine called CM512 in 110 healthy volunteers and people with moderate to severe eczema (atopic dermatitis). The main goal was to check if the drug is safe and how the body handles it. Participants received either the drug or a placebo, and r…

This early-stage study tested an oral medication called KT-621 in 22 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and how the body processes the drug. Researchers also looked for signs that the drug might help control the condition,…

This study tested a cream called ruxolitinib in 241 adults with moderate eczema who had not gotten better with standard steroid creams. The goal was to see if the cream could reduce skin redness, swelling, and itching. Participants applied the cream or a placebo cream for a set p…

This study tested an experimental drug called ATI-2138 in 14 adults with moderate to severe atopic dermatitis (eczema). Participants took the drug for 12 weeks to see if it was safe and could improve their skin symptoms. The main goal was to check for side effects, while also mea…

This early-stage study tested an experimental pill called soquelitinib in 82 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check if the drug is safe and tolerable compared to a placebo. Researchers also looked at whether it could reduce eczema se…

This study tested a special cream containing a substance called butyrate, which is naturally found in the skin, to see if it helps children aged 6 to 36 months with eczema. The cream aims to improve the skin barrier and reduce inflammation. The study involved 100 children and mea…

This study looked at how an experimental medicine for eczema (PF-08049820) is absorbed when made in fast- or slow-release versions, and whether a high-fat meal changes that. Twelve healthy adults each tried five different versions of the pill. The results will help pick the best …

This study looked at how dupilumab affects the immune and genetic activity inside eczema skin lesions. Seventeen adults with moderate-to-severe eczema received the drug, and researchers measured changes in immune cells and gene activity over 12 weeks. The goal was to understand h…

This study looked at whether rocatinlimab, a drug for moderate-to-severe eczema, changes how well vaccines work. About 221 adults with eczema received either the drug or a placebo, then got tetanus and meningitis vaccines. The goal was to see if their immune response was differen…

This study followed 487 pregnant women in Shanghai to see if key nutrients like folate and vitamin D affect their baby's chance of developing eczema (atopic dermatitis) by 6 months old. Researchers measured nutrient levels in the mothers' blood and checked babies for eczema. The …

This study looked at the genes in the skin of 433 people with eczema (atopic dermatitis) to find patterns that explain why some have mild symptoms and others have severe symptoms. Researchers collected skin samples and tracked how these patterns changed with standard treatments l…

This study looked at how staphylococcus bacteria on the skin may worsen eczema and increase the risk of herpes infections. Researchers compared skin and blood samples from 41 adults with moderate to severe eczema to healthy skin. The goal was to understand the bacteria's toxins a…

This study looked at skin samples from 170 people with psoriasis, atopic dermatitis (eczema), or healthy skin to understand how a protein called Lyn is involved in inflammation. Researchers measured Lyn activity and related enzymes in both affected and unaffected skin. The goal w…

This early-stage study tested a single dose of the experimental antibody SM17 in 30 healthy Chinese adults to see if it is safe and how the body processes it. The goal was not to treat any disease, but to gather important safety and drug-level information for future studies in co…

This study tested a single dose of rocatinlimab in 20 healthy Chinese adults to see how the drug moves through the body and if it is safe. The drug is being developed for atopic dermatitis (eczema). No treatment was given—only observation of drug levels and side effects.

This study looked at how a common bacteria, Staphylococcus aureus, affects skin inflammation in people with atopic dermatitis (eczema). Researchers applied patches containing the bacteria to the skin of 7 participants (both with and without eczema) to see if it caused a flare. Th…

This early-phase study looked at how rocatinlimab, a potential new treatment for moderate to severe eczema (atopic dermatitis), interacts with other common drugs. 21 adults with eczema took part. The goal was to measure drug levels in the blood and check for side effects, helping…

This study looked at eye problems in 100 adults with atopic dermatitis (eczema) who were treated with tralokinumab. The main goal was to find out how often eye issues like conjunctivitis happen within the first 4 months of treatment. Researchers hope this will help doctors better…

This study looked at how easy it is for parents to use a special website called OneBiome to track their baby's gut bacteria and eating habits. It included 60 infants in Singapore — some with early eczema and some healthy. The goal was to see if parents could understand and use th…

This study looked at 80 adults with moderate-to-severe atopic dermatitis whose condition is controlled by systemic treatments. Researchers wanted to understand how these patients use moisturizers (emollients) and what they expect from them. Participants filled out questionnaires …

This early-stage study tested a new medicine called 9MW1911 in 48 healthy adults to see if it is safe and how the body processes it. The goal was to find the right dose and check for side effects, not to treat any disease. Results will help guide future studies in people with ast…

This study looked at the types of fungi living on the skin of adults with atopic dermatitis (eczema) that affects the head and neck. Researchers compared the fungal makeup of 30 participants with eczema to healthy volunteers. The goal was to understand if differences in skin fung…

This study looked at how the body absorbs rocatinlimab, an experimental drug for atopic dermatitis (eczema), when given as a single shot using an autoinjector versus a traditional vial and syringe. It involved 231 healthy adults aged 18 to 60. The goal was to see if the autoinjec…

This study tested a new microneedle patch that collects fluid from the skin in 20 adults—some healthy, some with eczema. The goal was to see how much fluid could be collected and how well people tolerated the procedure. This early-stage research aims to improve how we study skin …

This study looked at how the body processes rocatinlimab when given as a shot from a vial versus a prefilled syringe. It involved 240 healthy adults aged 18 to 65. The goal was to see if both methods work the same way, not to treat any disease.

This study followed 461 children ages 6-8 whose mothers took a special nutritional drink before and during pregnancy. Researchers measured the children's growth, body composition, thinking skills, and metabolism to understand how parents' diet and lifestyle early on influence lon…

This study tested specially engineered versions of a natural immune protein (IL-2) in blood samples from 67 people with autoimmune or inflammatory diseases like lupus, multiple sclerosis, and rheumatoid arthritis. The goal was to see if these modified proteins could selectively a…